Jade Biosciences Reports $40.4M Q1 Loss, Secures $311.3M Cash for 2026 Trials
Jade Biosciences ended Q1 2026 with $311.3M in cash providing runway into H1 2028 and reported a net loss of $40.4M. The company will start Phase 2 JADE101 and Phase 1 JADE201 trials in Q2 2026 with 2027 interim data, and begin a first-in-human JADE301 study mid-2027.
1. Balance Sheet and Financial Results
Jade Biosciences closed Q1 2026 with $311.3 million in cash, cash equivalents and investments, which is expected to fund operations into the first half of 2028. Research and development expenses rose to $36.1 million from $20.0 million year-over-year, general and administrative costs increased to $7.4 million from $3.4 million, and net loss widened to $40.4 million from $38.2 million.
2. Pipeline Milestones
The company plans to initiate a Phase 2 clinical trial of JADE101 in IgA nephropathy patients in the second quarter of 2026 with interim data expected in 2027. A Phase 1 study of JADE201 in rheumatoid arthritis patients is also set to begin in Q2 2026 with interim 2027 readouts, and a first-in-human trial of JADE301 is on track for mid-2027.
3. Leadership Appointments
Edward R. Conner was appointed Chief Medical Officer to lead Jade’s clinical development and regulatory strategy, while Dr. Andrew King was promoted to President of Research and Development to oversee the advancement of the company’s autoimmune therapy pipeline.